Tumor-derived insulin-like growth factor-binding protein-1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors.

Hiroyuki SuzukiHideki IwamotoTakahiro SekiToru NakamuraAtsutaka MasudaTakahiko SakaueToshimitsu TanakaYasuko ImamuraTakashi NiizekiMasahito NakanoShigeo ShimoseTomotake ShironoYu NodaNaoki KamachiMiwa SakaiKazutoyo MoritaMasamichi NakayamaTomoharu YoshizumiRyoko KuromatsuHirohisa YanoYihai CaoHironori KogaTakuji Torimura

Published in: Cancer communications (London, England) (2023)

Together, our data shed light on mechanisms underlying acquired resistance of HCC to antiangiogenic TKIs. Antiangiogenic TKIs induced an increase of tumor IGFBP-1, which promoted angiogenesis through activating the IGFBP-1-integrin α5β1 pathway. These data bolster the application of a new therapeutic concept by combining antiangiogenic TKIs with IGFBP-1 inhibitors.

Keyphrases

binding protein
electronic health record
big data
endothelial cells
high glucose
signaling pathway
diabetic rats
drug induced
data analysis
vascular endothelial growth factor
oxidative stress
cell adhesion
cell migration